DEF 14A: NanoViricides Sets 2025 Annual Meeting Agenda

NanoViricides, Inc. announced its 2025 Annual Meeting of Stockholders to address director re-election, executive compensation, auditor ratification, and provided updates on related party transactions and clinical trials.

Summary

• The Annual Meeting of Stockholders will be held on Saturday, November 8, 2025, at 10:00 a.m. Eastern Daylight Time, at the Hampton Inn & Suites Stamford, CT.
• Stockholders will vote on the re-election of Anil Diwan as a Class I director for a two-year term expiring at the 2027 annual meeting.
• An advisory vote on the compensation of the company's named Executive Officers will be conducted.
• The appointment of EisnerAmper, LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2026, will be ratified.
• The company reported accounts payable to TheraCour Pharma, Inc. of approximately $584,000 as of June 30, 2025, down from $720,000 in 2024.
• Development fees charged by TheraCour Pharma, Inc. were approximately $2,490,000 for the fiscal year ended June 30, 2025, compared to $2,550,000 in 2024.
• A $1,500,000 cash milestone payment due to TheraCour Pharma, Inc. for Phase I clinical trial initiation was converted into 331,859 shares of Series A preferred stock on October 27, 2023, with approximately $49,800 in accrued interest cancelled.
• The company's President and Chairman, Anil Diwan, has provided a standby Line of Credit, increased to $3,000,000, with a maturity extended to March 31, 2027, though no amounts have been drawn as of the filing date.
• Clinical trial costs payable to Karveer Meditech, Private, Limited (KMPL) were $9,932 for FY2025 and $442,845 for FY2024, with accounts payable to KMPL at $237,367 as of June 30, 2025.
• Two new International PCT patent applications related to Coronavirus antiviral drugs were filed, with nominal expiry dates extending to at least June 24, 2041, and potentially into 2043 with regulatory extensions.

Sentiment

Score: 5

Explanation: The filing presents a mixed outlook. While there's progress in clinical trials and patent protection, the significant reliance on related party transactions for funding, R&D, and manufacturing, coupled with explicit mentions of needing to raise capital, introduces notable financial and governance concerns. The extension of the CEO's line of credit and the deferral of cash milestone payments to TheraCour highlight ongoing liquidity challenges, balancing against the positive developments in drug development.

Positives

• The Board of Directors includes three independent members (Makarand Jawadekar, Theodore Rokita, Brian Zucker) out of four, meeting NYSE American independence requirements.
• The Audit, Compensation, and Nominating and Corporate Governance Committees are comprised of independent directors, enhancing corporate oversight.
• New PCT patent applications for Coronavirus antiviral drugs provide significant commercial runway, potentially extending patent protection until 2043.
• The company has a Code of Ethics and established policies for related party transactions, aiming to align interests with stockholders.
• The company's licensee, KMPL, has commenced Phase Ia/Ib clinical trials for NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies in India, indicating progress in drug development.

Negatives

• The company has significant reliance on TheraCour Pharma, Inc., a related party where the President and Chairman, Anil Diwan, owns approximately 90% of the capital stock, for technology licensing, R&D, and manufacturing.
• Substantial development fees and future milestone payments are owed to TheraCour Pharma, Inc., creating ongoing financial obligations to a related entity.
• The company's need for capital is highlighted by the suspension of the advance payment requirement to TheraCour Pharma, Inc. until sufficient capital is raised.
• The conversion of a $1,500,000 cash milestone payment into Series A preferred stock for TheraCour Pharma, Inc. indicates cash flow constraints.
• The CFO, Meeta Vyas, is married to the President and Chairman, Anil Diwan, which, despite governance policies, presents a potential for perceived conflicts of interest in compensation and related party dealings.

Risks

• Heavy dependence on TheraCour Pharma, Inc. for intellectual property, research, development, and manufacturing, which is controlled by the company's President and Chairman, poses concentration risk.
• The company's ability to raise sufficient capital is critical, as indicated by the suspension of advance payments to TheraCour, which could impact ongoing development and operations.
• Future cash milestone payments to TheraCour Pharma, Inc. are contingent on 'revenue events,' which may delay or complicate the company's financial planning and liquidity.
• The success of drug candidates, particularly for COVID-19, is subject to the outcomes of ongoing clinical trials and regulatory approvals, which are inherently uncertain.
• The company's financial health is closely tied to the progress and commercialization of its licensed technologies, which are still in development phases.

Future Outlook

The company anticipates continued development of its antiviral drug candidates, particularly for Coronavirus infections, with patent coverage extending potentially until 2043. Future cash milestone payments to TheraCour Pharma, Inc. are now tied to the achievement of 'revenue events,' which could impact the timing of these obligations. The company also expects to continue its clinical trials in India through its licensee KMPL.

Management Comments

• "On behalf of the Board of Directors of NanoViricides, Inc. (the Company), I cordially invite you to attend the Annual Meeting of Stockholders."
• "Our Board of Directors unanimously recommends that you vote FOR each proposal."
• "REGARDLESS OF WHETHER YOU PLAN TO ATTEND THE ANNUAL MEETING, I URGE YOU TO VOTE BY COMPLETING AND RETURNING YOUR PROXY CARD AS SOON AS POSSIBLE. YOUR VOTE IS IMPORTANT AND WILL BE GREATLY APPRECIATED."

Industry Context

NanoViricides operates in the biopharmaceutical industry, focusing on antiviral drug development using its proprietary nanomedicine technology. The company's efforts in developing treatments for Coronavirus infections, including COVID-19, place it within a highly competitive and rapidly evolving segment of the pharmaceutical market. The reliance on licensing agreements and external clinical trial management (KMPL in India) is a common strategy for smaller biotech firms to advance drug candidates, but also introduces dependencies.

Comparison to Industry Standards

• The company's executive compensation structure, linking a portion of compensation to overall performance and growth, aligns with general industry best practices for attracting and retaining talent in the biopharmaceutical sector.
• The board composition, with a majority of independent directors and independent committees (Audit, Compensation, Nominating and Corporate Governance), meets NYSE American listing standards, which is a positive for corporate governance compared to some smaller public companies.
• The extensive related party transactions with TheraCour Pharma, Inc., including licensing, R&D, manufacturing rights, and significant milestone/royalty payments, are atypical for a company of this size and could be viewed as a governance concern compared to industry standards where arms-length transactions are preferred.
• The conversion of a $1.5 million cash milestone into preferred stock and the CEO providing a line of credit suggest potential funding challenges, which is not uncommon for early-stage biotech companies but highlights a reliance on internal/related party financing rather than broader market access.

Management Changes

Corporate Governance

Related Party Transactions

• Anil Diwan, President and Chairman, owns approximately 90% of TheraCour Pharma, Inc., which licenses core technologies to NanoViricides.
• NanoViricides has multiple exclusive, perpetual license agreements with TheraCour Pharma, Inc. for various antiviral drug candidates (HIV/AIDS, Influenza, Herpes, Hepatitis, Rabies, Dengue, Ebola/Marburg, Japanese Encephalitis, viral Conjunctivitis, Ocular Herpes, Varicella Zoster Virus, Coronavirus).
• TheraCour Pharma, Inc. retains the exclusive right to develop and manufacture licensed drugs, charging NanoViricides development fees (costs plus up to 30% of certain direct costs) and 15% royalties on net sales.
• Accounts payable to TheraCour Pharma, Inc. were $584,000 (June 30, 2025) and $720,000 (June 30, 2024), with development fees of $2,490,000 (FY2025) and $2,550,000 (FY2024).
• A $1,500,000 cash milestone payment to TheraCour Pharma, Inc. was converted into 331,859 shares of Series A preferred stock on October 27, 2023, with approximately $49,800 in accrued interest cancelled.
• The requirement for NanoViricides to maintain an advance payment to TheraCour Pharma, Inc. was suspended on February 12, 2024, until sufficient capital is raised.
• An amendment to the COVID License Agreement on February 13, 2024, stipulates that unearned cash milestone payments to TheraCour Pharma, Inc. are only due upon a 'revenue event' and limited to 50% of recognized revenue.
• Anil Diwan provided a standby Line of Credit to the company, increased to $3,000,000 with a 12% interest rate and maturity extended to March 31, 2027, collateralized by company assets. No amounts have been drawn.
• Meeta Vyas, Chief Financial Officer, is married to Anil Diwan. Her compensation includes a base salary of $10,800 per month and health insurance reimbursement up to $2,500 per month.
• NanoViricides has a license agreement with Karveer Meditech, Private, Limited (KMPL) for drug candidates in India, where KMPL acts as clinical trials manager and is reimbursed for costs plus a 30% fee. NanoViricides receives 70% royalty on net sales from KMPL.

Stakeholder Impact

• **Shareholders:** Will vote on key governance matters including director re-election, executive compensation, and auditor ratification. The extensive related party transactions and potential capital raise could impact future share value and dilution.
• **Employees:** Executive officers' compensation is subject to an advisory vote, and their employment agreements are detailed. No broader employee impact is explicitly mentioned.
• **TheraCour Pharma, Inc.:** Continues to be a critical partner, receiving significant development fees, milestone payments (some deferred or converted to equity), and future royalties, directly benefiting Anil Diwan as its principal owner.
• **Karveer Meditech, Private, Limited (KMPL):** Benefits from reimbursement of clinical trial costs plus a management fee, while bearing the responsibility for advancing drug candidates in India.
• **Creditors:** The Line of Credit provided by Anil Diwan, collateralized by company assets, impacts the company's debt structure and potential claims on assets.

Next Steps

• Hold the Annual Meeting of Stockholders on November 8, 2025, to vote on director re-election, executive compensation, and auditor ratification.
• Continue to advance the NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies through Phase Ia/Ib clinical trials in India via licensee KMPL.
• Seek to raise sufficient capital to address liquidity needs and potentially resume advance payments to TheraCour Pharma, Inc.
• Further develop and potentially commercialize antiviral drug candidates covered by new PCT patent applications.

Key Dates

Recommendation

The filing highlights both ongoing progress in clinical development and significant financial dependencies on related parties. The re-election of the founder and the ratification of auditors are routine. However, the extensive related party transactions with TheraCour, including deferred cash milestones and the CEO's personal line of credit, indicate potential liquidity challenges and governance concerns. While the patent coverage and clinical trial advancements are positive, the financial structure and reliance on related party funding introduce considerable risk. A 'hold' recommendation is appropriate as the company navigates these complexities, with investors needing to closely monitor capital raising efforts and the progress of clinical trials and commercialization to assess future value.

Keywords

NanoViricides, NNVC, SEC filing, proxy statement, annual meeting, corporate governance, executive compensation, director election, related party transactions, TheraCour Pharma, COVID-19, antiviral drugs, clinical trials, intellectual property, biotechnology, pharmaceuticals